Cargando…

Age-Related Medicine

A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahlich, John, Orlu, Mine, Mair, Alpana, Stegemann, Sven, van Riet-Nales, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523864/
https://www.ncbi.nlm.nih.gov/pubmed/30970554
http://dx.doi.org/10.3390/pharmaceutics11040172
_version_ 1783419433217163264
author Wahlich, John
Orlu, Mine
Mair, Alpana
Stegemann, Sven
van Riet-Nales, Diana
author_facet Wahlich, John
Orlu, Mine
Mair, Alpana
Stegemann, Sven
van Riet-Nales, Diana
author_sort Wahlich, John
collection PubMed
description A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual ages. The way in which regulatory authorities are encouraging the development of age-appropriate medicines was highlighted. Examples were provided of the difficulties faced by the older population with some medicinal products and suggestions given as to how the pharmaceutical scientist can build the requirements of the older population into their development of new medicines, as well as improvements to existing ones.
format Online
Article
Text
id pubmed-6523864
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65238642019-06-04 Age-Related Medicine Wahlich, John Orlu, Mine Mair, Alpana Stegemann, Sven van Riet-Nales, Diana Pharmaceutics Meeting Report A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual ages. The way in which regulatory authorities are encouraging the development of age-appropriate medicines was highlighted. Examples were provided of the difficulties faced by the older population with some medicinal products and suggestions given as to how the pharmaceutical scientist can build the requirements of the older population into their development of new medicines, as well as improvements to existing ones. MDPI 2019-04-09 /pmc/articles/PMC6523864/ /pubmed/30970554 http://dx.doi.org/10.3390/pharmaceutics11040172 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Meeting Report
Wahlich, John
Orlu, Mine
Mair, Alpana
Stegemann, Sven
van Riet-Nales, Diana
Age-Related Medicine
title Age-Related Medicine
title_full Age-Related Medicine
title_fullStr Age-Related Medicine
title_full_unstemmed Age-Related Medicine
title_short Age-Related Medicine
title_sort age-related medicine
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523864/
https://www.ncbi.nlm.nih.gov/pubmed/30970554
http://dx.doi.org/10.3390/pharmaceutics11040172
work_keys_str_mv AT wahlichjohn agerelatedmedicine
AT orlumine agerelatedmedicine
AT mairalpana agerelatedmedicine
AT stegemannsven agerelatedmedicine
AT vanrietnalesdiana agerelatedmedicine